European Commission Approves TREMFYA® (guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union

. FOR MEDICAL AND TRADE MEDIA ONLY Janssen’s guselkumab is the first biologic to be approved that selectively blocks interleukin (IL)-23.

BEERSE, Belgium Nov. 23, 2017 /PRNewswire/ — Janssen-Cilag International NV announced today that the European Commission (EC) has approved TREMFYA (guselkumab)….


Read all

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.